ESC 365 - Effectiveness of evolocumab for patients with familial hypercholesteraemia (FH) in European clinical practice

ESC Premium Access

Effectiveness of evolocumab for patients with familial hypercholesteraemia (FH) in European clinical practice

Session: Poster Session 1 - Lipids

Topic: Drug therapy

Speaker: Professor K. Ray (London, GB)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Professor Kausik K Ray

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)

91 presentations

16 followers

14 more presentations in this session

Patient characteristics and treatment patterns in patients on lipid-lowering therapies following an acute coronary syndrome in France

Speaker: Professor E. Bruckert (Paris, FR)

What is the most important residual risk after achievement of appropriate low-density lipoprotein cholesterol lowering therapy in secondary prevention of Japanese patients?

Speaker: Doctor A. Endo (Izumo, JP)

Association of adherence and treatment intensity of lipid-lowering therapy with cardiovascular outcomes and all-cause mortality in very high-risk patients in Germany

Speaker: Professor I. Ahrens (Cologne, DE)

Relative fat mass (RFM) is a better predictor of dyslipidemia and metabolic syndrome than body mass index (BMI).

Speaker: Doctor O. Kobo (Hadera, IL)

Low levels of low density lipoprotein cholesterol and cardiovascular, cancer and all-cause mortality outcomes

Speaker: Professor K. Sung (Seoul, KR)

Access the full session

Poster Session 1 - Lipids

Speakers: Professor K. Ray, Professor E. Bruckert, Doctor A. Endo, Professor I. Ahrens, Doctor O. Kobo...

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources